# Mankind Pharma (MANKIND) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/mankind

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,540
- Change: +0.87%
- As of: 2026-11-06
- 1D return: +0.87%
- 5D return: +1.89%
- 1M return: +6.72%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

Mankind Pharma (₹2,540) exhibits a strong daily uptrend with price trading above all key moving averages and the Supertrend. The ADX of 25.24 confirms established trend strength on the daily chart, supported by recent high-participation anomalies in late October. However, this bullish momentum is tempered by a bearish monthly Supertrend and weak monthly ADX (13.75), indicating a lack of conviction in the longer-term structure. Price sits near the upper end of its 20-day (+94.2%) and 50-day (+94.2%) ranges, suggesting limited immediate upside room before encountering resistance at ₹2,554–₹2,557. Risk remains elevated with an annualized volatility of 29.3% and a current drawdown of -13.5%. A break above ₹2,557 could confirm further daily gains, while a close below the pivot support at ₹2,525 would signal weakening daily momentum.

- Daily trend is established (ADX 25.24) with price above all MAs and Supertrend; Monthly trend shows conflict with bearish Supertrend and weak ADX (13.75).
- Price is near multi-decade highs: +86.1% from 252-day low and +94.2% from 20/50-day range highs.
- Immediate resistance at ₹2,554–₹2,557 (0.57–0.67% above); Pivot support at ₹2,525 (0.60% below).
- High volatility environment (ATR 2.8%, Annualized Vol 29.3%) with current drawdown of -13.5%.

- Inside Bar
- Doji
- Harami
- Bullish Engulfing Reversal
- Bearish Engulfing Reversal

### Official Filings

Mankind Pharma Limited’s Board approved unaudited financial results for Q2 and H1 FY27 on October 26, 2026, alongside two schemes of amalgamation. The company reported strong operational growth, with Q2 revenue rising 17.3% YoY to ₹4,338 crores and PAT increasing 37.7% to ₹716 crores. Management highlighted a net debt reduction to ₹2,639 crores (0.6x adjusted EBITDA) and confirmed progress toward repaying acquisition-related debt by FY28.

Structurally, the Board approved merging wholly owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited into the parent company, with an appointed date of April 1, 2027. A second scheme involves merging Upakarma Ayurveda Private Limited into Mankind Consumer Products Private Limited. Both require statutory approvals, including from the National Company Law Tribunal (NCLT). Additionally, the Commissioner of Income Tax (Appeals) deleted aggregate disallowances of ₹369.44 crore for FY 2013-14 to FY 2016-17 on technical grounds, though income-tax proceedings remain subject to further appeal.

Looking ahead, management will participate in an investor conference hosted by Ashika Stock Services Limited in Mumbai on November 5, 2026. The company stated that no unpublished price-sensitive information would be disclosed during these meetings.

- Q2 FY27 Performance: Revenue grew 17.3% YoY to ₹4,338 crores; PAT rose 37.7% to ₹716 crores; EBITDA margin improved to 27.1% (+210 bps YoY).
- Capital Structure & Debt: Net debt reduced to ₹2,639 crores (0.6x adjusted EBITDA); management remains on track to repay acquisition-related debt by FY28.
- Amalgamation Schemes: Board approved merger of Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma (Appointed Date: April 1, 2027) and Upakarma Ayurveda into Mankind Consumer Products; both await NCLT and statutory approvals.
- Tax Order Update: Commissioner of Appeals deleted disallowances of ₹369.44 crore for FY 2013-14 to FY 2016-17; authorities retain the right to challenge these orders.

- [MANKIND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261103_172258948.xml)
- [Mankind Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND4_03112026173858_Intimation-sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND1_30102026151831_CoveringTranscript_sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261030_173453751.xml)
- [Mankind Pharma Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating](https://nsearchives.nseindia.com/corporate/MANKIND1_29102026202928_20261029_CreditRatings_CRISILSD.pdf)
- [Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026131052_CoverNPsd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026171310_InvestorPresentationsdfinal.pdf)
- [Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026150743_Outcome26102026sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Scheme of Arrangement |SUBJECT: Scheme of Arrangement](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026151215_Outcome26102026sd.pdf)
- [Please find attached outcome of Board Meeting where Board has noted the merger of MCPPL & UAPL |SUBJECT: Scheme of Arrangement](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026151729_Outcome26102026sd.pdf)

### Fundamentals

Mankind Pharma demonstrates robust top-line momentum and improving earnings quality, anchored by strong cash generation. For the trailing twelve months (TTM) ending September 2026, sales grew 14% to ₹15,379 crore, while operating profit surged 35% to ₹4,077 crore. This leverage resulted in a 33% TTM profit growth to ₹2,264 crore and an EPS of ₹54.31, up from ₹46.34 for FY2026. The most critical signal is the conversion of this accounting profit into cash: Cash from Operating Activities rose sharply to ₹3,121 crore in FY2026, with CFO/EBITDA at 102%, indicating high earnings quality.

Financial health has improved significantly as the company deleveraged. Borrowings fell from ₹8,511 crore in Mar 2025 to ₹5,422 crore by Sep 2026, supported by net financing outflows of ₹2,953 crore in FY2026. However, efficiency metrics show mixed signals; the Cash Conversion Cycle lengthened to 117 days in Mar 2026 from 120 days in Mar 2024, driven largely by higher inventory holding (193 days) and extended payables (121 days). Return on Capital Employed (ROCE) declined to 14% in Mar 2026 from 26% in Mar 2024, reflecting the impact of increased working capital requirements despite stable fixed assets. Institutional interest shifted, with DIIs increasing their stake to 15.54% in Sep 2026, while FIIs reduced theirs to 9.37%.

- Earnings Quality & Cash Flow: TTM Net Profit reached ₹2,264 crore with strong cash realization; CFO hit ₹3,121 crore in FY2026, confirming that profit growth is backed by actual cash inflows rather than accruals.
- Leverage Reduction: Total borrowings decreased steadily to ₹5,422 crore by Sep 2026 from ₹8,511 crore in Mar 2025, reducing financial risk and supporting free cash flow generation.
- Efficiency Headwinds: ROCE contracted to 14% in Mar 2026 due to rising working capital intensity; Inventory Days rose to 193 and Days Payable to 121, offsetting gains in debtor management.
- Institutional Shift: Domestic Institutional Investors (DIIs) increased holdings to 15.54% in Sep 2026, while Foreign Institutional Investors (FIIs) trimmed positions to 9.37%, signaling a change in investor composition.

### Bull Case

Mankind Pharma operates in a pharmaceutical sector experiencing robust momentum, with India’s medicine sales growing 12% year-on-year in the September quarter. This double-digit growth, sustained for four consecutive quarters, is driven by chronic care demand and regulatory consolidation that has closed non-compliant small units. For Mankind, this structural tailwind provides a constructive backdrop, potentially supporting market share gains as smaller competitors exit. Technically, the stock shows short-term resilience; it rose +0.9% on 6 November 2026 to close at ₹2,540, with daily and weekly Supertrend indicators signaling bullish momentum. The stock has also delivered strong medium-term returns, including +17.3% year-to-date and +14.8% over the past 10 days, indicating active buying interest despite a longer-term monthly bearish trend.

- Sector Tailwinds: India’s pharma sales grew 12% YoY in Q2 FY27 (September quarter), marking the fourth straight quarter of double-digit growth led by chronic care drugs and regulatory closures of non-compliant units.
- Short-Term Technical Strength: Daily and weekly Supertrend indicators are bullish, with the stock closing at ₹2,540 on 6 Nov 2026 after a +0.9% daily gain.
- Recent Price Momentum: The stock has posted +14.8% return over the last 10 days and +17.3% YTD, contrasting with a -11.8% return since the start of its tracking period.
- Market Context: A GST cut from 12% to 5% and rising consumer consciousness regarding chronic diseases are cited as key drivers for the current sector expansion.

- [India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-medicine-sales-grow-in-double-digits-for-four-straight-quarters-led-by-chronic-care-drugs/articleshow/135435486.cms)
- [MANKIND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261103_172258948.xml)
- [Mankind Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND4_03112026173858_Intimation-sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND1_30102026151831_CoveringTranscript_sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261030_173453751.xml)
- [Mankind Pharma Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating](https://nsearchives.nseindia.com/corporate/MANKIND1_29102026202928_20261029_CreditRatings_CRISILSD.pdf)
- [Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026131052_CoverNPsd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026171310_InvestorPresentationsdfinal.pdf)
- [Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026150743_Outcome26102026sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Scheme of Arrangement |SUBJECT: Scheme of Arrangement](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026151215_Outcome26102026sd.pdf)

### Bear Case

Mankind Pharma faces a notable divergence between its long-term price performance and recent technical structure, signaling potential near-term volatility. While the stock has delivered a +17.3% year-to-date return as of 6 November 2026, it is currently trading in a -13.5% drawdown from its peak, with a historical maximum drawdown of -34.4%. This indicates significant price erosion over time despite recent gains.

Technically, the monthly trend is bearish, contrasting with bullish daily and weekly signals, which suggests underlying medium-term weakness or consolidation pressure. The stock closed at ₹2,540 on 6 November 2026, facing immediate resistance just above at ₹2,554.47 (0.57% away). With an annualized volatility of +29.3% and an Average True Range (ATR) of 2.8%, the equity exhibits high sensitivity to market movements. Investors should monitor whether the price can sustainably break above the ₹2,554–₹2,557 resistance cluster; failure to do so may reinforce the bearish monthly momentum.

- Stock is in a -13.5% current drawdown from its peak, reflecting substantial prior price erosion despite a +17.3% YTD return.
- Monthly technical trend is bearish, contrasting with bullish daily/weekly signals, indicating mixed medium-term momentum.
- Immediate resistance lies at ₹2,554.47 (0.57% above), with high volatility (+29.3% annualized) suggesting sensitive price action.
- Support levels are clustered lower at ₹2,524.73 (-0.60%) and ₹2,497.51 (-1.67%), requiring defense to maintain current price stability.

- [India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-medicine-sales-grow-in-double-digits-for-four-straight-quarters-led-by-chronic-care-drugs/articleshow/135435486.cms)
- [MANKIND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261103_172258948.xml)
- [Mankind Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND4_03112026173858_Intimation-sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND1_30102026151831_CoveringTranscript_sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261030_173453751.xml)
- [Mankind Pharma Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating](https://nsearchives.nseindia.com/corporate/MANKIND1_29102026202928_20261029_CreditRatings_CRISILSD.pdf)
- [Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026131052_CoverNPsd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026171310_InvestorPresentationsdfinal.pdf)
- [Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026150743_Outcome26102026sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Scheme of Arrangement |SUBJECT: Scheme of Arrangement](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026151215_Outcome26102026sd.pdf)

### FAQs

**What were Mankind Pharma's key financial results for Q2 FY27, and how do they compare to the previous year?**

For Q2 FY27 (ended September 30, 2026), Mankind Pharma reported revenue of ₹4,338 crores, up 17.3% year-on-year. Profit after tax (PAT) rose 37.7% to ₹716 crores, while EBITDA margins expanded by 210 basis points to 27.1%. The company also reduced net debt to ₹2,639 crores, resulting in a net debt-to-adjusted EBITDA ratio of 0.6x.

**Is Mankind Pharma planning any investor engagement or meetings in early November 2026?**

Yes. Management is scheduled to participate in an investor conference hosted by Ashika Stock Services Limited in Mumbai on November 5, 2026. The agenda includes one-on-one and group meetings for business updates. The company confirmed that no unpublished price-sensitive information outside the public domain will be disclosed during these sessions.

**How has CRISIL Ratings recently updated its view on Mankind Pharma's credit instruments?**

On October 29, 2026, CRISIL Ratings reaffirmed ratings for two instruments totaling ₹2,500 crore (₹400 crore and ₹2,100 crore). Additionally, CRISIL withdrew ratings for another instrument worth ₹2,500 crore and a Commercial Paper program rated A1+ with a limit of ₹1,500 crore.

**What are the current technical support and resistance levels for Mankind Pharma stock?**

As of November 6, 2026, with the stock closing at ₹2,540, immediate resistance lies at ₹2,554.47 and ₹2,556.95. Key support levels are observed at ₹2,524.73 (pivot), ₹2,497.51, and ₹2,488.27. The daily trend shows a bullish Supertrend direction, while the monthly trend remains bearish.

- [India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-medicine-sales-grow-in-double-digits-for-four-straight-quarters-led-by-chronic-care-drugs/articleshow/135435486.cms)
- [MANKIND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261103_172258948.xml)
- [Mankind Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND4_03112026173858_Intimation-sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MANKIND1_30102026151831_CoveringTranscript_sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261030_173453751.xml)
- [Mankind Pharma Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating](https://nsearchives.nseindia.com/corporate/MANKIND1_29102026202928_20261029_CreditRatings_CRISILSD.pdf)
- [Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026131052_CoverNPsd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026171310_InvestorPresentationsdfinal.pdf)
- [Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026150743_Outcome26102026sd.pdf)
- [Mankind Pharma Limited has informed the Exchange about Scheme of Arrangement |SUBJECT: Scheme of Arrangement](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026151215_Outcome26102026sd.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Strong Uptrend
- Weekly trend: Weak Uptrend
- Pivot point: ₹2,524.73
- Risk regime: Price Risk Requires Attention

### Support levels
- 2497.5051513671874
- 2412.5125
- 2344.6279296875

### Resistance levels
- 2556.95
- 2635.13603515625
- 2667.75

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.87% |
| return_10 | +14.80% |
| return_1m | +1.60% |
| return_1y | +10.00% |
| return_20 | +6.72% |
| return_3m | +4.95% |
| return_5 | +1.89% |
| return_6m | +7.58% |
| return_since_start | -11.84% |
| return_ytd | +17.34% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -34.39% |
| annualized_volatility | +29.29% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and Pre-Tax Profit Rise, but Higher Tax Expense Moderates Net Profit Growth

Mankind Pharma reported higher revenue and a sharp increase in profit before tax during the first quarter of FY2026‑27. The improvement in pre‑tax earnings was helped by a substantial drop in finance costs. However, a much larger tax expense limited the rise in net profit, which grew moderately from a year earlier and only slightly from the previous quarter.

## Revenue and Profit Before Tax

Revenue from operations was ₹4,030.59 crore in Q1 FY2026‑27, compared with ₹3,570.35 crore in the same quarter last year and ₹3,442.93 crore in the preceding quarter. The year‑on‑year growth was 12.9%, while the sequential increase of 17.1% followed three quarters of declining revenue.

Profit before tax (PBT) rose to ₹765.51 crore, up 42.5% from ₹537.32 crore a year earlier and 16.7% from ₹656.18 crore in the previous quarter. As a percentage of revenue, PBT improved from 15.0% in Q1 FY2025‑26 to 19.0% in the current quarter, meaning revenue grew faster than total costs before tax.

## Finance Costs and Other Expenses

Finance costs fell to ₹109.98 crore, a decline of 35.6% year‑on‑year from ₹170.65 crore and 22.4% sequentially from ₹141.75 crore. This reduction contributed directly to the higher pre‑tax profit.

Other expenses increased to ₹962.63 crore from ₹886.58 crore a year earlier, a rise of 8.6%. As a share of revenue, other expenses declined from 24.8% to 23.9%, so these costs grew at a slower pace than revenue.

## Tax Expense and Net Profit

The tax expense was ₹195.36 crore, up from ₹95.87 crore a year earlier and ₹99.75 crore in the previous quarter. The effective tax rate moved from 17.8% in Q1 FY2025‑26 to 25.5% in the current quarter.

Net profit (profit for the period) came in at ₹574.09 crore, 29.1% higher than the ₹444.62 crore posted a year ago but only 2.6% above the ₹559.42 crore recorded in the preceding quarter. The large increase in the tax expense absorbed much of the pre‑tax profit growth, holding the sequential net profit rise to a small amount.

## Earnings Per Share and Comprehensive Income

Basic earnings per share were ₹13.76, up from ₹10.62 a year earlier and from ₹13.44 sequentially. Diluted earnings per share showed a similar pattern.

Comprehensive income for the period was ₹553.78 crore, up 24.8% year‑on‑year from ₹443.86 crore but down 5.9% sequentially from ₹588.36 crore. The sequential decline in comprehensive income, while net profit rose, indicates that other comprehensive income was negative in the quarter.

## Key Takeaway

Mankind Pharma’s revenue increased, and pre‑tax profit grew sharply with the help of lower finance costs. However, a significantly higher tax expense reduced the amount of that gain that reached the bottom line. Net profit rose year‑on‑year but showed only a modest sequential increase as the effective tax rate moved from 17.8% to 25.5%.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +72.63%
- FII holding: +9.45%
- DII holding: +15.39%
- Mutual fund holding: +10.87%
- Retail holding: +1.29%
- Promoter pledged: +0.00%

### Major reported shareholders

- Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee) — +20.18% (Trusts)
- Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee) — +19.35% (Trusts)
- Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee) — +14.95% (Trusts)
- SHEETAL ARORA — +4.67%
- PUJA JUNEJA — +2.79%
- NPS TRUST - A/C SBI PENSION FUND SCHEME - CORPORAT — +2.77%
- POONAM JUNEJA — +2.56%
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIF — +2.07%
- ARJUN JUNEJA — +1.97%
- RAMESH JUNEJA — +1.66%

## Official filings

- 2026-11-06 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_06112026155831_FilingIntimationInvestorsCall06112026.pdf)
- 2026-11-06 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261106_160211538.xml)
- 2026-11-03 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261103_172258948.xml)
- 2026-11-03 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND4_03112026173858_Intimation-sd.pdf)
- 2026-10-30 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_30102026151831_CoveringTranscript_sd.pdf)
- 2026-10-30 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261030_173453751.xml)
- 2026-10-29 — Credit Rating Update: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_29102026202928_20261029_CreditRatings_CRISILSD.pdf)
- 2026-10-27 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026131052_CoverNPsd.pdf)
- 2026-10-27 — Earnings Presentation: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_27102026171310_InvestorPresentationsdfinal.pdf)
- 2026-10-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026150743_Outcome26102026sd.pdf)
- 2026-10-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026151215_Outcome26102026sd.pdf)
- 2026-10-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026151729_Outcome26102026sd.pdf)
- 2026-10-26 — Press Release: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026152348_CoverPRsd.pdf)
- 2026-10-26 — Earnings Presentation: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026152911_CoverPRsd.pdf)
- 2026-10-26 — Earnings Presentation: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026163105_Investor_Presentation.pdf)
- 2026-10-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_21117_WebXMLFile_20261026_183442884.xml)
- 2026-10-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_21117_WebXMLFile_20261026_185002023.xml)
- 2026-10-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26102026194044_AudioRecordingsd.pdf)
- 2026-10-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261026_195841910.xml)
- 2026-10-26 — Financial Results Filing: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1746296_26102026085927_WEB.xml)
- 2026-10-26 — Financial Results Filing: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1746311_26102026091828_WEB.xml)
- 2026-10-22 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_22102026154333_Revised_Intimation_of_Earning_Call_sd.pdf)
- 2026-10-22 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_22102026155758_IntimationInvestorsCall22102026sd.pdf)
- 2026-10-22 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_22102026184828_Revised_Intimation_of_Earning_Call_sd.pdf)
- 2026-10-22 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20261022_194232798.xml)

## News and market events

- 2026-11-01 — Economic Times: **India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs** — India's pharmaceutical sector recorded double-digit sales growth for four straight quarters, with the September quarter showing 12% year-on-year growth to Rs 70,180 crore, led by chronic care segments. This trend contrasts with the slower 6%-8% growth seen in most of 2025 and is attributed to CDSCO-driven closures of non-compliant small units, a GST cut from 12% to 5%, and rising consumer consciousness regarding chronic diseases. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-medicine-sales-grow-in-double-digits-for-four-straight-quarters-led-by-chronic-care-drugs/articleshow/135435486.cms)
- 2026-10-30 — Economic Times: **Stocks in news: RIL, Jio, Trent, Suzlon Energy, IndiGo, Vedanta Power and RVNL** — Trent reported a 25.3% YoY increase in consolidated profit to Rs 468.09 crore for Q2FY27, with revenue climbing 22%. Lodha Developers is among the companies scheduled to release their second-quarter earnings results on October 30. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-ril-jio-trent-suzlon-energy-indigo-vedanta-power-and-rvnl/articleshow/135324704.cms)
- 2026-10-27 — MONEYCONTROL: **Mankind Pharma stock surges 9% after strong Q2 results; Kotak sees big upside, other brokerages cautious** — Mankind Pharma stock surges 9% after strong Q2 results; Kotak sees big upside, other brokerages cautious Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio IPO Allotment Jio IPO Listing Date Israel Elections 2026 live Microsoft Buyout news Gyanesh Kumar Benjamin Netanyahu Noel Tata Ather Share Price Anthropic IPO News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX Price Go — [Source](https://www.moneycontrol.com/news/business/markets/mankind-pharma-stock-surges-9-after-strong-q2-results-kotak-sees-big-upside-other-brokerages-cautious-14061229.html)
- 2026-10-27 — Economic Times: **Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore** — Mankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, supported by domestic and export growth, while EBITDA margins expanded 210 basis points. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/mankind-pharma-shares-jump-8-as-q2-profit-rises-38-to-rs-716-crore/articleshow/135227555.cms)
- 2026-10-27 — CNBC-TV18: **Mankind Pharma jumps 8% on Q2 earnings beat but here's why analysts remain concerned** — Of the 22 analysts covering Mankind Pharma, 15 have given it a "Buy" recommendation, three have a "Hold" rating, and the stock has four "Sell" ratings. — [Source](https://www.cnbctv18.com/market/mankind-pharma-share-price-q2-result-reaction-key-area-of-concern-buy-sell-growth-avenues-outlook-returns-20020057.htm)
- 2026-10-27 — BUSINESS: **Mankind Pharma soars 11% in 2 days on strong Q2 earnings; brokerages upbeat** — Mankind Pharma share price: Going ahead, improving domestic volumes, rising chronic contribution and sustained export momentum are expected to support growth, say analysts. — [Source](https://www.business-standard.com/markets/news/mankind-pharma-share-price-soars-11-in-2-days-on-strong-q2-earnings-brokerages-upbeat-126102700209_1.html)
- 2026-10-27 — Economic Times: **Mankind Pharma Q2 profit rises 38% to Rs 716 crore** — Mankind Pharma has announced a profit increase of 37.7% to ₹716 crore during the September quarter. Revenue from operations rose to ₹4,337.9 crore compared to ₹3,697.2 crore in the same quarter last year. This growth is attributed to strong performance in both domestic and international markets. The recent acquisition of Armed Cell Therapeutics is expected to enhance R&D capabilities. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/mankind-pharma-q2-profit-rises-38-to-rs-716-crore/articleshow/135222585.cms)
- 2026-10-27 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Aegis Logistics (₹1,291) – BUY** — Sensex, Nifty, Share Prices Live: Aegis Logistics share price to go higher towards ₹1,500 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-27-october-2026/article71626702.ece)
- 2026-10-26 — CNBC-TV18: **Top Stories | Bulls return to Dalal Street, Anthropic IPO spotlight, Israel's big vote** — Top 10@10 — CNBC-TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial highlights — delivered at 10 pm. — [Source](https://www.cnbctv18.com/business/top-stories-bulls-return-to-dalal-street-anthropic-ipo-spotlight-israels-big-vote-20019703.htm)
- 2026-10-26 — Economic Times: **Mankind Pharma shares key business developments from Q2 & H1 of FY27** — The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mankind-pharma-shares-key-business-developments-from-q2-h1-of-fy27/articleshow/135211681.cms)
- 2026-10-26 — CNBC-TV18: **Mankind Pharma Q2 profit jumps 39% to ₹712 crore as revenue rises 17%** — Mankind Pharma’s operating margin widened to 27% from 24.9% a year earlier. Its board also approved plans to merge two wholly owned subsidiaries into the company. — [Source](https://www.cnbctv18.com/market/earnings/mankind-pharma-q2-profit-jumps-39-to-rs712-crore-as-revenue-rises-17-20019468.htm)
- 2026-10-26 — MONEYCONTROL: **Mankind Pharma stock surges 4.5% as Q2 profit jumps 39%, revenue rises 17%** — Mankind Pharma stock surges 4.5% as Q2 profit jumps 39%, revenue rises 17% Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio IPO Allotment Jamia Protest UP Polls 2027 Rahul Gandhi Infosys Share Price Aamir Khan Small Cap Stocks Cyclone Arnab Dhanush News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX Price Gold MCX Price Personal Finance more Home Loans up to 50 Lakhs Cre — [Source](https://www.moneycontrol.com/news/business/markets/mankind-pharma-stock-surges-4-5-as-q2-profit-jumps-39-revenue-rises-17-14060288.html)
- 2026-10-26 — Mint: **Q2 results 2026 today, schedule: Paytm, Tata Con, REC among 90 firms to announce quarterly earnings | Full list** — Q2 results 2026 today, schedule: Among the key companies set to report their quarterly earnings today are Paytm, Mankind Pharma, Tata Consumer Products, ITC Hotels and REC. — [Source](https://www.livemint.com/market/stock-market-news/q2-results-2026-today-schedule-paytm-tata-con-rec-among-90-firms-to-announce-quarterly-earnings-full-list-11792983346368.html)
- 2026-09-30 — Mint: **Raja Venkatraman recommends two stocks for 30 September** — Market expert Raja Venkatraman shares his top stock picks for 30 September. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-two-stocks-for-30-september-11790730993565.html)
- 2026-09-29 — MONEYCONTROL: **Pharma stocks gain on US tariff exemption on some specialty drugs** — pharma stocks — [Source](https://www.moneycontrol.com/news/business/markets/pharma-stocks-gain-on-us-tariff-exemption-on-some-specialty-drugs-14040978.html)
- 2026-09-27 — MONEYCONTROL: **Broader markets underperform, extend losing streak to third week** — Midcap,Smallcap,Broader indices,Market this week,midcap this week,smallcap this week — [Source](https://www.moneycontrol.com/news/business/markets/broader-markets-underperform-extend-losing-streak-to-third-week-14039106.html)
- 2026-09-22 — REDIFF.COM: **Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies** — India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies. — [Source](https://www.rediff.com/business/report/indias-top-10-pharma-companies-sustain-volume-growth-outperforming-smaller-rivals/20260922.htm)
- 2026-09-22 — BUSINESSTODAY: **Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare** — Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare — [Source](https://www.businesstoday.in/industry/pharma/story/heres-why-chryscapital-expects-20-25-of-the-latest-2-2-billion-fund-to-go-to-pharma-healthcare-557090-2026-09-22)
- 2026-09-22 — Mint: **Mankind Pharma shares up 10% in just 4 sessions; Kotak upgrades the stock - Target, share price trend** — Mankind Pharma shares rose more than 2% in intraday trade on the BSE on Tuesday, 22 September, defying weak stock market sentiment. At the price of  ₹2,481, Mankind Pharma stock has gained 10.4% in just four sessions. — [Source](https://www.livemint.com/market/stock-market-news/mankind-pharma-shares-up-10-in-just-4-sessions-kotak-securities-upgrades-the-stock-target-share-price-trend-11790061865907.html)
- 2026-09-22 — CNBC-TV18: **11:11 | India’s economy could triple in 10 years; Bitcoin surges past $87,000; Trump-Xi dinner draws tech chiefs** — JPMorgan CEO Jamie Dimon says India’s economy could triple over the next decade as the bank plans further expansion in the country. Bitcoin jumps above $87,000, while Microsoft’s Satya Nadella is set to join tech CEOs at the Trump-Xi state dinner. Plus, brokerage calls on Sansera Engineering and Mankind Pharma, rupee and gold moves, and more in today’s 11:11 roundup. — [Source](https://www.cnbctv18.com/business/india-economy-could-triple-in-10-years-bitcoin-surges-past-87000-trump-xi-dinner-draws-tech-chiefs-19995422.htm)
- 2026-09-22 — CNBC-TV18: **Mankind Pharma shares get an upgrade from Kotak; Price target among top five on the street** — According to Kotak Institutional Equities, Mankind Pharma's base domestic business is finally showing tangible signs of recovery after a prolonged restructuring impact, thereby becoming one of the key reasons behind its upgrade for the stock. — [Source](https://www.cnbctv18.com/market/mankind-pharma-share-price-upgrade-kotak-buy-target-upside-business-recovery-volumes-new-launches-returns-19995386.htm)
- 2026-09-21 — MONEYCONTROL: **Pharma stocks rise up to 6% amid defensive buying, strong product pipeline; Mankind Pharma, Wockhardt lead gains** — Pharma stocks, Sun Pharma — [Source](https://www.moneycontrol.com/news/business/markets/pharma-stocks-rise-up-to-6-amid-defensive-buying-strong-product-pipeline-mankind-pharma-wockhardt-lead-gains-14034517.html)
- 2026-09-20 — Economic Times: **Chalet Hotels in advanced talks to buy Six Senses Vana for 600 crore** — Chalet Hotels is on the verge of acquiring Six Senses Vana in Dehradun, a luxurious wellness retreat owned by Veer Singh, son of Analjit Singh. Valued at roughly six hundred crore rupees, this deal highlights Chalet's commitment to expanding its footprint in the high-end hospitality market while concurrently developing other upscale properties throughout India. — [Source](https://economictimes.indiatimes.com/industry/services/hotels-/-restaurants/chalet-hotels-in-advanced-talks-to-buy-six-senses-vana-for-600-crore/articleshow/134374818.cms)
- 2026-09-18 — Mint: **Pulse oximeters, glucometers at grocery stores? Centre plans rule change | Mint** — The move is aimed at reducing compliance requirements for low-risk products that health authorities want to make more widely available. — [Source](https://www.livemint.com/industry/pulse-oximeters-pregnancy-kits-bp-monitoring-machines-retail-sales-india-11789668774172.html)
- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical and healthcare products.

### Business segments
- **Pharmaceutical Formulations:** This segment addresses both acute and chronic therapeutic areas, offering formulations for conditions such as anti-infectives, cardiovascular diseases, gastrointestinal disorders, anti-diabetic treatments, dermatological issues, erectile dysfunction, and anti-allergic treatments.
- **Consumer Healthcare Products:** The company also has a significant presence in the consumer healthcare products market, focusing on manufacturing, packaging, and marketing these products.

### Competitive strengths
- Diverse product portfolio across multiple therapeutic areas.
- Extensive manufacturing, packaging, and marketing capabilities.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/mankind
Markdown representation: https://faxioms.com/stocks/mankind?render=md